Motion - Screening and surveillance of Barrett's epithelium is practical and cost effective: Arguments against the motion;Proposition: Le dépistage et la surveillance de l'épithélium de Barrett sont pratiques et rentables - Arguments contre la proposition

Canadian Journal of Gastroenterology

Volumn 16, Issue 8, 2002, Pages 541-545

  Chiba, Naoki ^a  

^a Surrey GI Clinic   (Canada)

Author keywords

Barrett's esophagus; Esophageal adenocarcinoma

Indexed keywords

ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CANCER SCREENING; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DEATH; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; HEALTH SURVEY; HUMAN; HUMAN TISSUE; LIFESPAN; MEDICAL DECISION MAKING; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SCREENING TEST; TIME; WORLD HEALTH ORGANIZATION;

EID: 0036698052     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/354181     Document Type: Article

References (27)

1. Blustein PK, Beck PL, Meddings JB, et al. The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms. Am J Gastroenterol 1998;93:2508-12.
2. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
3. de Mas Chr-R, Krämer M, Seifert E, Rippin G, Vieth M, Stolte M. Short Barrett: prevalence and risk factors. Scand J Gastroenterol 1999;34:1065-70.
4. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
5. Farrow DC, Vaughan TL, Sweeney C, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000;11:231-8.
6. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol 1999;94:86-91.
7. Sampliner RE, and the Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998;93:1028-32.
8. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
9. DeMeester SR, DeMeester TR. The diagnosis and management of Barrett's esophagus. Adv Surg 1999;33:29-68.
10. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
11. Gudlaugsdottir S, van Blankenstein M, Dees J, Wilson JH. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol 2001;13:639-45.
12. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-93.
13. Eloubeidi MA, Provenzale D. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol 1999;94:937-43.
14. Nandurkar S, Talley NJ. Barrett's esophagus: the long and the short of it. Am J Gastroenterol 1999;94:30-40.
15. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalovski M. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol 1997;92:407-13.
16. Van der Burgh A, Dees J, Hop WCJ, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's esophagus. Gut 1996;39:5-8.
17. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-22.
18. Levine DS. Management of dysplasia in the columnar-lined esophagus. Gastroenterol Clin North Am 1997;26:613-34.
19. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994;89:670-80.
20. Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990;113:373-84.
21. Tengs TO, Meyer G, Siegel JE, Pliskin JS, Graham JD, Weinstein MC. Oregon's Medicaid ranking and cost-effectiveness: is there any relationship? Med Decis Making 1996;2:99-107.
22. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
23. Pennock JL, Oyer PE, Reitz BA, et al. Cardiac transplantation in perspective for the future. Survival, complications, rehabilitation, and cost. J Thorac Cardiovasc Surg 1982;83:168-77.
24. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
25. Krishnadath KK, Reid BJ, Wang KK. Biomarkers in Barrett esophagus. Mayo Clin Proc 2001;76:438-46
26. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999;94:3413-9.
27. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.